Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: Experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 study

Diabetologia

Volumn 54, Issue 6, 2011, Pages 1308-1317

  Mellbin, L G ^a   Malmberg, K ^a   Norhammar, A ^a   Wedel, H ^b   Ryden L ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

Author keywords

Cardiac complications; Clinical diabetes; Insulin therapy; Macrovascular disease; Malignancies; Metformin; Oral pharmacological agents

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLIBENCLAMIDE; INSULIN; LONG ACTING DRUG; METFORMIN; SHORT ACTING DRUG; SULFONYLUREA; TICLOPIDINE; ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EVENING DOSAGE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; HEART INFARCTION; LONGITUDINAL STUDY; MIDDLE AGED; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LONGITUDINAL STUDIES; MALE; METFORMIN; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80052522584     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2084-x     Document Type: Article

References (34)

1. Ryden L, Standl E, Bartnik M et al (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force onDiabetes and CardiovascularDiseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28:88-136 (Pubitemid 46137814)
2. Anselmino M, Malmberg K, Ohrvik J, Ryden L (2008) Evidencebased medication and revascularization: powerful tools in the management of patients with diabetes and coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur J Cardiovasc Prev Rehabil 15:216-223 (Pubitemid 351507656)
3. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591 (Pubitemid 351214285)
4. [No authors listed] (2006) Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. WHO, Geneva
5. Skyler JS, Bergenstal R, Bonow RO et al (2009) Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of theAmerican College of Cardiology Foundation and the American Heart Association. Circulation 119:351-357
6. Ryden L, Malmberg K, Mellbin L (2009) Is glucose normalization an evidence-based treatment for patients with type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 5:8-9
7. Patel A, MacMahon S, Chalmers J et al (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572 (Pubitemid 351831357)
8. Gerstein HC, Miller ME, Byington RP et al (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559 (Pubitemid 351831356)
9. Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. Jama 298:1189-1195 (Pubitemid 47403105)
10. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. Jama 298:1180-1188 (Pubitemid 47403104)
11. Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52: 1732-1744
12. Currie CJ, Poole CD, Gale EA (2009) The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 52:1766-1777
13. Jonasson JM, Ljung R, Talback M, Haglund B, Gudbjornsdottir S, Steineck G (2009) Insulin glargine use and short-term incidence of malignancies - a population-based follow-up study in Sweden. Diabetologia 52:1745-1754
14. Colhoun HM, SDRN Epidemiology Group (2009) Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 52:1755-1765, Erratum 52: 2469
15. Malmberg K, Ryden L, Efendic S et al (1995) Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI Study): effects on mortality at 1 year. J Am Coll Cardiol 26:57-65
16. Malmberg K, Ryden L, Wedel H et al (2005) Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26:650-661 (Pubitemid 40516876)
17. Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L (2008) The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 29:166-176
18. [No authors listed] (1996) Acute myocardial infarction: prehospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 17:43-63
19. Van de Werf F, Ardissino D, Betriu A et al (2003) Management of acute myocardial infarction in patients presenting with STsegment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 24:28-66
20. Aas AM, Ohrvik J, Malmberg K, Ryden L, Birkeland KI (2009) Insulin-induced weight gain and cardiovascular events in patients with type 2 diabetes. A report from the DIGAMI 2 Study. Diabetes Obes Metab 11:323-329
21. Norhammar A, Lindback J, Ryden L, Wallentin L, Stenestrand U (2007) Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart 93:1577-1583 (Pubitemid 350205554)
22. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653 (Pubitemid 41817713)
23. UKPDS33 (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853
24. UKPDS34 (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865
25. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393 (Pubitemid 36159355)
26. Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L (2008) Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established butalso in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29:177-184
27. Bailey CJ (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc Drugs Ther 22: 215-224
28. Kooy A, de Jager J, Lehert P et al (2009) Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169:616-625
29. Giovannucci E, Michaud D (2007) The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 132:2208-2225 (Pubitemid 46693749)
30. Holly JM, Perks CM (2008) Cancer as an endocrine problem. Best Pract Res Clin Endocrinol Metab 22:539-550
31. Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258 (Pubitemid 44106500)
32. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM (2009) New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625
33. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273 (Pubitemid 44799743)
34. Schimmack G, Defronzo RA, Musi N (2006) AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes Metab 8:591-602 (Pubitemid 44515556)